Technical Analysis for ANNX - Annexon, Inc.

Grade Last Price % Change Price Change
D 27.45 13.34% 3.23
ANNX closed up 13.34 percent on Friday, January 15, 2021, on 1.17 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Up
Historical ANNX trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Resistance Bearish 13.34%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 13.34%
Wide Bands Range Expansion 13.34%
Oversold Stochastic Weakness 13.34%
Older End-of-Day Signals for ANNX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 10% 1 day ago
Up 1 ATR 1 day ago
Rose Above 20 DMA 1 day ago
20 DMA Resistance 1 day ago
Up 5% 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Annexon, Inc. Description

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Immunology Eye Immune System Monoclonal Antibody Ophthalmic Antibody Biomarker Degenerative Disease Autoimmunity Platform Technology Neurodegenerative Disorders Complement System Intravitreal Administration

Is ANNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 31.94
52 Week Low 15.33
Average Volume 117,773
200-Day Moving Average 0.00
50-Day Moving Average 24.91
20-Day Moving Average 25.82
10-Day Moving Average 23.29
Average True Range 1.97
ADX 18.02
+DI 31.23
-DI 20.92
Chandelier Exit (Long, 3 ATRs ) 26.02
Chandelier Exit (Short, 3 ATRs ) 27.54
Upper Bollinger Band 31.77
Lower Bollinger Band 19.87
Percent B (%b) 0.64
BandWidth 46.07
MACD Line -0.50
MACD Signal Line -0.47
MACD Histogram -0.0368
Fundamentals Value
Market Cap 1.05 Billion
Num Shares 38.2 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -122.44
Price-to-Sales 0.00
Price-to-Book 2.60
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.56
Resistance 3 (R3) 32.96 30.34 32.54
Resistance 2 (R2) 30.34 28.78 30.63 32.20
Resistance 1 (R1) 28.89 27.82 29.62 29.49 31.86
Pivot Point 26.27 26.27 26.63 26.56 26.27
Support 1 (S1) 24.82 24.71 25.55 25.42 23.04
Support 2 (S2) 22.20 23.75 22.49 22.70
Support 3 (S3) 20.75 22.20 22.36
Support 4 (S4) 21.35